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S300 Poster Session IIsignificantly affect the patient’s quality of life. To evaluate incidences
and outcomes of VZV reactivation after cord blood transplantation
(CBT) by comparison with those after unrelated bone marrow trans-
plantation (uBMT), we retrospectively analyzed the records of 387
adult patients who underwent CBT or uBMT for the first time at
our hospital between January, 2002 and March, 2010, and survived
more than 50 days after transplantation without lost to follow-up
or re-transplantation before day 50. All patients received long-
term prophylaxis with oral acyclovir (ACV) at 200 mg/day against
VZV reactivation. 108 patients discontinued ACV at a median of
439 days (range 42-1655 days), whereas the remaining 279 continued
it until the end of follow-up. Between 50 days and 5 years after trans-
plantation, 45 patients (32 CBT and 13 uBMT) developed VZV re-
activation at a median of 591 days (range 58-1292 days), with
a cumulative incidence of 21.5%. Although the 5-year cumulative in-
cidence of VZV reactivation tended to be higher in CBT recipients
than in uBMT recipients, the difference did not reach statistical sig-
nificance (26.8% vs. 15.0%, P5 0.14). Themedian onset of VZV re-
activation did not show a significant difference between the both
groups (549 days vs. 676 days, P5 0.60). Two patients developed lo-
calized diseases within 100 days, because of early discontinuation of
ACV. Beyond 100 days after transplantation, 31 of the 165 CBT re-
cipients (18.8%) and 12 of the 116 uBMT recipients (10.3%) devel-
oped VZV reactivation, the 5-year cumulative incidence of which
was significantly higher after CBT than after uBMT (34.1% vs.
16.3%, P 5 0.028). Although breakthrough reactivation seemed to
occur more frequent in CBT recipients (14.3% vs. 4.8%, P 5
0.11), rate of dissemination was almost similar between the both
groups (7.0% vs. 5.4%, P 5 0.55). All patients were successfully
treated with antiviral agents. No important predictors were found
to be associated with VZV reactivation after CBT, while older age
(Age . 5 50) was identified as an independent risk factor for VZV
reactivation beyond 100 days after uBMT. These findings suggested
that clinical outcomes of VZV reactivation after CBT were compa-
rable to those after uBMT, in spite of the relative higher incidence of
VZV reactivation after CBT.403
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Allogeneic hematopoietic cell transplantation (HCT) remains the
only curative treatment strategy for patients with MDS or CMML.
Recent reduction of the transplant related toxicity has permitted
the expansion of empiric age limitations for HCT up to 75 years.
There has been limited comparative data onHCT focusing on donor
availability in patients with MDS/CMML. Between January 2004
and September 2009, a total of 255 new patients (NP) with a diagno-
sis of MDS or CMML were evaluated for HCT at Moffitt Cancer
Center. This report describes the outcomes of these patients with
emphasis on donor availability.
Donor Search Results:Of the 255 NP, 58 did not undergo a donor
search and not included in the survival analysis. Of the 197 patients
who had a donor search initiated, a sibling (SIB) matched unrelated
(MUD) or single HLA antigen/allele mismatch (mMUD) unrelated
adult donor was found in 173 patients and not identified in the re-
maining 24 patients. To mitigate bias due to factors giving a survival
advantage to patients who were stable enough to survive the donor
search and obtain aHCT, the survival analysis included only patients
alive 90 days after the donor search was initiated.We have identified
donors within this time frame for 99%of the patients who ever found
one, although time to transplant is longer. At the 90 days landmark,there were 164 patient in the Donor cohort, and 19 patients in the
No Donor cohort.
Donor Cohort:The median age was 56.6 yrs (18.5 – 73.5). Ninety-
seven patients (59%) were older than 55 yrs. Donors were SIB (60),
MUD (75) and mMUD (29). Median follow-up of surviving patients
is 27.7months (7.2 – 70.7).
No Donor Cohort: Median age was 57.4 yrs (32.6 – 68.1) with 12
patients (63%) older than 55 yrs. Median follow-up is 9.2 months
(1.4 – 61.5).
Outcomes: Patients with a donor had significantly improved overall
survival from time of donor search vs. patients with no donor (P 5
0.007) with 2 year OS of 48% vs. 23%, respectively.
Transplant:Of the 164 in donor group, 121 (74%) patients received
HCT. The 2-year overall survival (OS) after transplantation is sim-
ilar for SIB (51%), MUD (39%) or mMUD (68%) transplant recip-
ients (P5 0.4), and also similar by age below or above 55 years (P5
0.7). These data demonstrate that most patients with MDS or
CMML can have a suitable donor identified and proceed to HCT.
Overall survival is significantly improved for those patients who
have a suitable sibling or unrelated donor.404
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To evaluate the efficacy and toxicity of RIC regimen including flu-
dara. and TBI with the introduction of rituximab for allo-HSCT, we
conducted a prospective study for CLL patients aged\ 65 years in
stage B or C in response after a salvage treatment, having a HLA
identical sibling donor. The conditioning included: rituxi-
mab375mg/m2 on day-5, fludarabine30 mg/m2 from day-4 to day-
2, TBI 2grays on day0 and rituximab500mg/m2 on day1 and day8.
Forty patients were included, 34 (85%) males and 6 females, median
age 54 years (35-65), 38 (95%) in B stage and 2 in stage C. Among 23
explored for cytogenetics, 8 were abnormal. Before transplantation,
17 patients received 2 lines treatment, 10 three lines, 13$ 5 lines. At
time of allograft, 7 (17%) patients were CR, 29 (73%) in PR and 4
(10%)\ PR, 59% were sex-mismatched. For ABO matching, 68%
were compatible, 19% major incomp. & 13% minor incopm. The
median interval diagnosis-allo-HSCTwas 58 months (6-177). Seven
(17%) patients did not receive rituximab during conditioning be-
cause the protocol did not include it at the beginning and has been
amended later.Thirty-nine (98%) patients engrafted with a median
time to neutrophils recovery of 20 days (11-70), 79% of patients
reached a total donor chimerism at day 90. Seventeen patients devel-
oped aGVHDgrade$ II (8 grII, 8 grIII & 1 grIV) with a cumulative
incidence at 3 months of 44% (36-52). The cumulative incidence of
cGVHD was, at 12 months: 29% (21-36) for lim. and ext.; at 18
months: 32% (24-40) lim. and 42% (34-50) ext.. After a median fol-
low-up of 28 months (3-71), the median OS was not reached with 5-
years probability of 55%(41-74). The median time of EFS was 30
months (15 - 70) with a 5-years probability of 46%(33-66). The cu-
mulative incidence of relapse at 1 and 3 years was 17% (11-23) and
22% (15-29) respectively. The cumulative incidence TRM at 1 and
3 years was 10% (5-15) and 27% (20-35) respectively. At the last fol-
low-up, 17 patients died, 6 due to relapse and 11 due to TRM. The
multivariate analysis showed a positive impact of rituximab on OS
and EFS [HR 5 0.1 [0-0.6] p 5 0.02 & HR 5 0.1[0-0.4] p 5
0.035 respectively.The introduction of rituximab allowed a better
outcome especially a significant reduction of incidence and severity
of acute GVHD. Nevertheless there was still a high incidence of
cGVHD, leading us to propose either to increase the number of
Poster Session II S301rituximab injections after allo-HSCT, or to test Fludarabine/busi-
lvex/ATG associated to rituximab.405
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Background: Haploidentical stem cell transplantation (Haplo-
HSCT) has been developed as an alternative transplant strategy for
children with hematological disorders without a HLA matched do-
nor. Reduced-intensity conditioning (RIC) regimens allow haplo-
HSCT with less toxicity and have been used in children with good
results. Haplo-HSCT with RIC has been also carried out an outpa-
tient setting, but such strategy has not been extensively explored in
children.
Methods:We analyzed the outcome of fifteen consecutive paediat-
ric patients with various hematological diseases who underwent
a Haplo-HSCT using a RIC regimen and CD3/CD19 depletion in
an outpatient setting at our institution from January, 2009 to July,
2010. Stem-cell source was peripheral blood of mismatched family
donors. A uniform preparative regimen consisting of fludarabine, cy-
clophosphamide, antithymocyte globulin and melphalan was used.
Results: The grafts contained a median of 10x106 (range, 6.7–
18x106) CD34+ cells, and 10.7x105 (range, 2-21x105) CD3+ T cells.
Engraftment of neutrophils and platelets was achieved at a median of
14 (11 - 60) days and 14 (11 - 54) days, respectively. Ten patients en-
grafted with full donor chimerism. The regimen was well tolerated
withmaximum acute toxicity being grade 2mucositis in two patients.
Four patients experienced aGVHD $ grade II, two responded to
prednisone and cyclosporine, the others have to additionally receive
alemtuzumab with good initial response. One patient developed lim-
ited cGVHD and another developed extensive cGVHD. Two pa-
tients died due to infections and transplant related mortality was
20%. Twelve of fifteen patients (80%) showed transient or sustained
engraftment, five of them (33%) are free of disease with complete
chimerism at a median follow up of 9 months.
Conclusions: Our results suggest that Haplo-HSCT can be a rea-
sonable therapeutic alternative for children who have no family do-
nor or cord blood units available and that is possible to carry it out on
an outpatient basis.Table 1. Post- transplant characteristics and current status for 15 p
Case
Day of
ANC > 500
Day of PLT
> 20000 Chimerism aGVHD
1 +20 +17 Complete Skin grade I
2 +13 +17 Complete Skin grade III
3 +14 +11 Complete Skin grade I
4 +22 +20 90% Skin grade I
5 +13 +54 86% Skin grade II
6 +60 +14 13% No
7 +14 +11 Complete No
8 +27 +15 No No
9 +32 +32 No No
10 +14 +11 Complete Skin grade I and
Intestine grade II
11 +11 +13 Complete Skin grade I and
Intestine grade III
12 +30 +14 No No
13 +14 +14 80% No
14 +34 +40 10% No
15 +14 +12 Complete Skin grade I406
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Combined related haploidentical-unrelated umbilical cord blood
stem cell transplants (RH-UUCB SCT) is a new approach for treat-
ment of patients with hematological malignancies who lack HLA
matched donors.. Although additional cells from the haploidentical
donor reduce complications associated with late engraftment in
UUCB SCT, patients with RH-UUCB SCT are challenged with
a higher degree of HLA disparities and potential complication asso-
ciated with them.
In order to evaluate the impact of donor-specific HLA antibodies
(DSA) on outcome of high risk RH-UUCB SCTs, we enrolled 30
patients with hematologic malignancies and one with Severe aplastic
anemia who were transplanted between January 2007 and December
2009. Patient sera on pre-transplant, days 0, 7, 14, 28, 75, 100, and
180 were tested for HLA antibodies using Luminex based solid-
phase assays.
Twenty nine patients had either pre-SCT and/or post-SCT
specimens for antibody testing. Nineteen of 29 had pre-SCT spec-
imens (13:19 had no HLA antibodies; 7:19 had HLA antibodies
and only 3 of them had DSA). Of those, one died 3 days post-
SCT and cannot be evaluated; the second patient had DSA against
UCB with mean fluorescence intensity (MFI) . 10,000. She en-
grafted promptly but engraftment analysis demonstrated only
haplo-donor engraftment. Patient three had DSA against the hap-
loidentical donor and the UCB (MFI. 1,500). This patient did not
engraft and died 50 days post-transplant. Two patients had non-
DSA HLA antibodies in pre- and post-SCT specimens. They
both engrafted promptly and over time developed durable cord en-
graftment. Among 21 evaluable patients without pre transplant
HLA antibodies, 15 engrafted with the cord, 4 failed to engraft
at all and 2 had durable haplo-engraftment without detectable
cord engraftment. Three developed HLA antibodies post trans-
plant, but these were not DSA.
In Conclusion 17% of patients had HLA antibodies pre-RH-
UUCB-SCT, but only 10% had DSA. One patient with both RH
and UUCB donor-specific HLA antibodies (MFI . 1,500) died of
graft failure. One patient with DSA (MFI . 10,000) against
UUCB engrafted the haplo-donor cells and survived 200 days.
Only 3 patients developed de novo HLA antibodies post-SCT, but
no DSA.
The risk of cord failure is higher in patients withDSA (2/2) than in
patients without DSA (6/21), (p 5 0.11, Fishers exact). Presence of
HLA antibodies and MFI should be determined pre-transplant and
these results should be used to guide donor selection.atients receiving a Haplo HSCT.
cGVHD Status/Time post-transplant
No Alive on remission/ 19 months
No Relapsed at 3 moths post-transplant/Died at 8
months post-transplant
No Alive-Remission/ 13 months
No Died due to Lymphoproliferative disease at 5 months.
Extensive Died with extensive GVHD/ 11 months
No Rejected graft at 3 months/Alive on remission/ 12 months
No Alive on remission/12months
No Graft failure/Died at 6 months post-transplant due
to graft failure-sepsis
No Graft failure/Died at 6 months post-transplant due to relapse.
No Died due to pneumonia at 3 months post-transplant
Limited Alive with limited GVHD/ 9 months
No Graft failure/Alive on remission/ 8 months
No Rejected graft at 3 months/Relapse at 6 months
No Graft failure/Alive on remission/ 6 months
No Alive on remission/ 6 months
